

APR. 17. 2006 3:54PM

NO. 2516 P. 1/19

RECEIVED
CENTRAL FAX CENTER
APR 17 2006

Shook,
Hardy &
Bacon, L.L.P.
www.shb.com

TO
MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS

PHONE

FAX
1.571.273.8300

Jean M. Dickman

FROM
JEAN M. DICKMAN

IT #
2463

MATTER #
TLAB.79219

2555 Grand Blvd.
Kansas City
Missouri 64108-2613
816.474.6550
816.421.5547 Fax
jdickman@shb.com

19 Pages Transmitted
Original Document Will Not Follow
If you experience any problems, please call 816.474.6550 extension 17517.

DATE
APRIL 17, 2006

COMMENTS:

ATTACHED:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

APPL. NO. 10/002,842
APPLICANT(S) JAMES HUNTER BOONE, ET AL.
FILED 11/14/2001
GROUP ART UNIT 1641
EXAMINER: LISA V. COOK

fax

Confidentiality Notice: The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual(s) or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for return of the original documents to us.

1956382v1

Geneva
Houston
Kansas City
London
Miami
Orange County
Overland Park
San Francisco
Tampa
Washington, D.C.

RECEIVED
CENTRAL FAX CENTER

APR 17 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/002,842 Confirmation No. 3654
Applicant(s) : James Hunter Boone, et al.
Filed : 11/14/2001
Group Art Unit : 1641
Examiner : Lisa V. Cook
Title : METHOD FOR DIFFERENTIATING IRRITABLE BOWEL SYNDROME
FROM INFLAMMATORY BOWEL DISEASE (IBD) AND FOR
MONITORING PERSONS WITH IBD USING TOTAL ENDOGENOUS
LACTOFERRIN AS A MARKER

Docket No. : TLAB.79219
Customer No. : 05251

CERTIFICATE OF TRANSMISSION
37 C.F.R. 1.8

I hereby certify that this correspondence is being facsimile
transmitted to the Commissioner for Patents at (571) 273-8300
on:

Date: April 17, 2006

VIA FACSIMILE 571-273-8300

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Enclosed herewith and listed on Form PTO-1449 (also enclosed) are photocopies of foreign patents or publications and/or other documents which Applicant(s) request be considered by the Examiner and made of record. These references were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Respectfully submitted.



Jean M. Dickman
Reg. No. 48,538

JMD:nlm
SHOOK, HARDY, & BACON LLP.
2555 Grand Boulevard
Kansas City, MO 64108-2613
TEL 816.474.6550 + FAX 816.421.5547

1936143v1

APR 17 2006

PTO/SB/089 (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/002,842
		Filing Date	11/14/2001
		First Named Inventor	James Hunter Boone, et al.
		Art Unit	1641
		Examiner Name	Lisa V. Cook
		Attorney Docket Number	TLAB.79219
Sheet 1	of 1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TIBBLE, J., TEAHON, K., THJODLEIFSSON, B., et al., "A Simple Method for Assessing Intestinal Inflammation in Crohn's Disease" Gut 2000;47-506-513.	
		SAITOH, O., KOJIMA, K., SUGI, K., et al., "Fecal Eosinophil Granule-Derived Proteins Reflect Disease Activity in Inflammatory Bowel Disease" AJG 1999; Vol 94 No. 12.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.